Pontifax

About

Portfolio · 37

Kamari Pharma

Small Molecule Inhibitors of TRPV3

Led ★ 2 rounds $23.0M committed Latest: 2025-06

Lutris Pharma

Anticancer Therapy for Patients Treated with EGFR Inhibitors

2 rounds $35.7M committed Latest: 2025-01

Pomvom

Digital Experiential Documentation Solution

1 round $5.3M committed Latest: 2025-01

Levation Pharma

Topical Oxymetazoline for Cosmetic Eye Lifts

1 round $1.9M committed Latest: 2022-06

EyeYon Medical

Ophthalmic Products for Vision-threatening Conditions

3 rounds $35.6M committed Latest: 2021-03

OCON Therapeutics

Spherical Intrauterine Drug Delivery Platform

Led ★ 3 rounds $9.5M committed Latest: 2020-12

V-Wave

Miniature Shunt for Treating Congestive Heart Failure

Led ★ 3 rounds $128.0M committed Latest: 2020-09

Fore Biotherapeutics

Precision Oncology Treatments

Led ★ 2 rounds $69.5M committed Latest: 2020-09

CytoReason

Machine Learning for Data-driven Target Discovery and Drug Development

1 round $2.8M committed Latest: 2020-01

Metabomed

Target-inhibiting Anticancer Drugs

2 rounds $30.5M committed Latest: 2019-12

Raziel Therapeutics

Injectable Drug for Treatment of Obesity

Led ★ 2 rounds $26.5M committed Latest: 2019-12

Pi Therapeutics

Inhibitors for Cancer Treatment

Led ★ 2 rounds $19.7M committed Latest: 2019-05

89bio

Treatment for Liver and Metabolic Disorders

1 round $60.0M committed Latest: 2018-10

Entera Bio

Oral Delivery of Therapeutic Proteins

2 rounds $9.5M committed Latest: 2017-10

CathWorks

Noninvasive FFR Measurements for Coronary Interventions

1 round $15.8M committed Latest: 2017-10

Eloxx Pharmaceuticals

Treatment of Rare Genetic Diseases

2 rounds $46.5M committed Latest: 2017-08

Tisbury Pharmaceuticals

Open-angle Glaucoma Treatment

1 round $32.0M committed Latest: 2017-06

LogicBio Therapeutics

Gene Therapy for Genetic and Infectious Diseases

1 round $45.0M committed Latest: 2017-06

Protekt Therapeutics

PKR Inhibition for Treating Neurodegenerative Diseases

1 round $8.0M committed Latest: 2017-05

ARTSaVIT

Cancer Apoptosis Technology

1 round Latest: 2017-01

Nutrinia

Neonatal Gastrointestinal Treatment

2 rounds $42.0M committed Latest: 2016-08

Sweetch

AI-Powered Hyper-Personalized Patient Engagement Platform

2 rounds $4.8M committed Latest: 2016-04

Avraham Pharmaceuticals

Prevention of Neurodegenerative Disorders

3 rounds $17.5M committed Latest: 2016-02

Otic Pharma

Foam-based Products for the Treatment of Ear, Nose, and Throat Disorders

1 round Latest: 2015-05

Check-Cap

Capsule-based Screening Technology for Detecting Colorectal Cancer

1 round $12.0M committed Latest: 2014-10

BioCEP

Cell Isolation Platform

1 round $5.3M committed Latest: 2014-02

HeadSense

Noninvasive Multiparameter Brain Monitoring

1 round Latest: 2013-07

UroGen Pharma

Urologic Oncology Therapies

2 rounds $8.5M committed Latest: 2013-05

Quiet Therapeutics

Anticancer Therapeutics Using Nanoparticles and Biomarkers

1 round $5.5M committed Latest: 2013-01

cCAM Biotherapeutics

Monoclonal Antibodies for Cancer Treatment

1 round $8.0M committed Latest: 2012-09

InsuLine Medical

Insulin Treatment Method

1 round $1.5M committed Latest: 2012-04

Stimatix GI

Stomal Management Solutions

1 round $1.0M committed Latest: 2011-03

Se-cure Pharmaceuticals

Botanical Drug Development

1 round $14.0M committed Latest: 2010-12

Interna Therapeutics

Drug Delivery via Electrical Nano Motors

2 rounds $10.3M committed Latest: 2010-05

ProtAb

Antibody for Treating Autoimmune Disorders

2 rounds $7.0M committed Latest: 2010-04

Applied Immune Technologies

TCRL Antibodies for Therapeutic Applications

1 round $4.0M committed Latest: 2010-04

ProMining Therapeutics

Drug Discovery Platform for Novel Oral Drugs

1 round

Investment activity

12 portfolio exits on record.

Funds · 6

• 6 — $404M Oct 2020
• 5 — $240M Jan 2018
• 4 — $175M Dec 2016
• 3 — $88M Jan 2011
• 2 — $80M Jan 2008
• 1 — $36M Dec 2004

Q&A

What is Pontifax's most recent fund close?

Pontifax closed Fund 6 in October 2020, raising $404 million.

What was a significant exit for Pontifax in the last two years?

In February 2026, Pontifax saw CathWorks acquired by Medtronic for $585 million. Another notable exit was V-Wave, acquired by Johnson & Johnson for $600 million in August 2024.

Which sectors does Pontifax primarily focus on for investments?

Pontifax primarily focuses on Health Tech & Life Sciences, with 34 portfolio companies in this sector.

Can you name some of Pontifax's public portfolio companies?

Pontifax has several public portfolio companies, including 89bio, Eloxx Pharmaceuticals, and UroGen Pharma.

What is the investment stage focus for Pontifax?

Pontifax invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.

Who are the co-founders of Pontifax?

The co-founders of Pontifax are Tomer Kariv, who serves as Co-Founder & CEO, and Ran Nussbaum, Co-founder & Managing Partner.

What was the size of Pontifax's Fund 5?

Pontifax closed Fund 5 in January 2018, raising $240 million.

Has Pontifax had any recent IPOs in its portfolio?

In November 2019, 89bio went public on NASDAQ, raising $85 million. LogicBio Therapeutics also went public on NASDAQ in October 2018, raising $70 million.